World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
67
Citations
19679
World Ranking
2651
National Ranking
1267

Bernard A. FoxEarle publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Bernard A. FoxEarle sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 310 publications — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Bernard A. FoxEarle D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Bernard A. FoxEarle sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 67 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Bernard A. FoxEarle is affiliated with the Earle A. Chiles Research Institute in the United States. Their research primarily focuses on medicine and immunology and microbiology, contributing extensively to oncology, immunology, molecular biology, infectious diseases, and radiology, nuclear medicine, and imaging.

Their work spans several main topics, including cancer immunotherapy and biomarkers, immunotherapy and immune responses, CAR-T cell therapy research, immune cell function and interaction, vaccines and immunoinformatics approaches, monoclonal and polyclonal antibodies research, and SARS-CoV-2 and COVID-19 research.

Frequent co-authors collaborating with FoxEarle include Shawn M. Jensen, Carlo Bifulco, Rom S. Leidner, Brian Piening, and Carmen Ballesteros-Merino.

The researcher has contributed to multiple publication venues, with many works appearing in Regular and Young Investigator Award Abstracts, Journal of Translational Medicine, Journal for ImmunoTherapy of Cancer, bioRxiv (Cold Spring Harbor Laboratory), and Cancer Research.

Representative recent publications include:

  • Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer, 2022, New England Journal of Medicine
  • Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer, 2020, Journal of Clinical Oncology
  • Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells, 2021, Nature Communications
  • Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC, 2022, Nature Communications
  • Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10, 2020, Journal for ImmunoTherapy of Cancer

In addition to journal articles, FoxEarle has published a book titled Cyber Mission Thread Analysis: An Implementation Guide for Process Planning and Execution, released in 2022 through RAND Corporation eBooks.

Best Publications

  • International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

    Franck Pagès;Bernhard Mlecnik;Florence Marliot;Gabriela Bindea;Gabriela Bindea;Gabriela Bindea

  • Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.

    Jérôme Galon;Jérôme Galon;Jérôme Galon;Bernhard Mlecnik;Bernhard Mlecnik;Bernhard Mlecnik;Gabriela Bindea;Gabriela Bindea;Gabriela Bindea;Helen K. Angell;Helen K. Angell;Helen K. Angell

  • Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans

    Gary J. Nabel;Elizabeth G. Nabel;Zhi Yong Yang;Bernard A. Fox

  • Cancer classification using the Immunoscore: a worldwide task force

    Jérôme Galon;Franck Pagès;Francesco M Marincola;Francesco M Marincola;Helen K Angell;Helen K Angell

  • Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

    Thomas Duhen;Rebekka Duhen;Ryan Montler;Jake Moses

  • The immune score as a new possible approach for the classification of cancer

    Jérôme Galon;Franck Pagès;Francesco M Marincola;Francesco M Marincola;Magdalena Thurin

  • OX40 is a potent immune-stimulating target in late-stage cancer patients.

    Brendan D. Curti;Magdalena Kovacsovics-Bankowski;Nicholas Morris;Edwin Walker

  • Cancer and inflammation: Promise for biologic therapy

    Sandra Demaria;Eli Pikarsky;Michael Karin;Lisa M. Coussens

  • Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy.

    Kristina H. Young;Jason R. Baird;Talicia Savage;Benjamin Cottam

  • Granulocyte–Macrophage Colony-Stimulating Factor Gene-Modified Autologous Tumor Vaccines in Non–Small-Cell Lung Cancer

    John Nemunaitis;Daniel Sterman;David Jablons;John W. Smith

  • Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.

    David J. Messenheimer;Shawn M. Jensen;Michael E. Afentoulis;Keith W. Wegmann

  • Novel technologies and emerging biomarkers for personalized cancer immunotherapy.

    Jianda Yuan;Priti S. Hegde;Raphael Clynes;Periklis G. Foukas;Periklis G. Foukas

  • Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX ® vaccine in advanced-stage non-small-cell lung cancer

    J Nemunaitis;T Jahan;H Ross;D Sterman

  • Future perspectives in melanoma research

    Paolo A. Ascierto;Sanjiv Agarwala;Gerardo Botti;Alessandra Cesano

  • Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.

    A E Chang;A Aruga;M J Cameron;V K Sondak

  • Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.

    Bernhard Mlecnik;Carlo Bifulco;Gabriela Bindea;Gabriela Bindea;Florence Marliot

  • Defining the critical hurdles in cancer immunotherapy

    Bernard A. Fox;Bernard A. Fox;Dolores J. Schendel;Lisa H. Butterfield;Steinar Aamdal

  • Immunotherapy of Malignancy by In Vivo Gene Transfer into Tumors

    Gary J. Nabel;Alfred Chang;Elizabeth G. Nabel;Gregory Plautz

  • Multiparametric immune profiling in HPV- oral squamous cell cancer.

    Zipei Feng;Daniel Bethmann;Matthias Kappler;Carmen Ballesteros-Merino

  • Gene-Modified Tumor Vaccine with Therapeutic Potential Shifts Tumor-Specific T Cell Response from a Type 2 to a Type 1 Cytokine Profile

    Hong-Ming Hu;Walter J. Urba;Bernard A. Fox

  • Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015.

    J Galon;J Galon;B A Fox;B A Fox;C B Bifulco;G Masucci

Frequent Co-Authors

Walter J. Urba
Walter J. Urba Providence Portland Medical Center
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Francesco M. Marincola
Francesco M. Marincola National Institutes of Health
Thomas F. Gajewski
Thomas F. Gajewski University of Chicago
Lisa H. Butterfield
Lisa H. Butterfield University of California, San Francisco
Yutaka Kawakami
Yutaka Kawakami International University Of Health And Welfare Atami Hospital
Toshihiko Torigoe
Toshihiko Torigoe Sapporo Medical University
Iris D. Nagtegaal
Iris D. Nagtegaal Radboud University
Pamela S. Ohashi
Pamela S. Ohashi Princess Margaret Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Immunology, expanding your expertise through healthcare-related degrees can open diverse career opportunities. One option to consider is the cheapest online pmhnp certificate programs, which offer an affordable pathway into specialized psychiatric nursing.

Advanced degrees such as a Doctor of Nursing Practice (DNP) often lead to higher earning potential, as outlined by data on doctorate in nursing salary. This makes pursuing a DNP a strategic choice for those seeking leadership roles in healthcare.

For nurses looking to shift their focus, transitioning from family nurse practitioner to acute care nurse practitioner is a promising route. Guidance on making this move effectively is available through resources like fnp to acnp.

Additionally, accelerated programs provide flexible, fast-track options to become nurse practitioners. Exploring the accelerated np programs online can help motivated students launch their careers quickly without compromising quality education.

Best Scientists Citing Bernard A. FoxEarle

Trending Scientists

Recently Published Articles